Bender F, Hartmann C, Brisse B, Wichmann B
Z Kardiol. 1975 Apr;64(4):329-37.
In view of the unsatisfying drug treatment of bradycardias in most cases, clinical studies with new compounds seem to be urgent. A report is given on experiences with a derivative of atropine (gen. Ipratropiumpromid) in 34 cases suffering from various types of bradycardias. Comparing heart rate following intravenous injections of 0.5 to 1.0 mg, the new drug proved to be definitely more effective than atropine sulfate. Side effects were limited to diminution of salivary glands function.
鉴于大多数情况下对心动过缓的药物治疗效果不尽人意,开展新型化合物的临床研究显得十分迫切。本文报告了对34例患有各种类型心动过缓的患者使用阿托品衍生物(通用名:异丙托溴铵)的经验。静脉注射0.5至1.0毫克后比较心率,结果表明这种新药明显比硫酸阿托品更有效。副作用仅限于唾液腺功能减退。